loarthritis (SpA) is needed to strengthen patient-level research in non-experimental clinical settings. A research network collaboration of registries collecting data on patients with SpA, "EuroSpA" offers opportunities to enhance research capabilities in the real world setting.

Objectives: To assess patient numbers, data extent and completeness in European SpA registries and establish an international research collaboration and common data set to address key data gaps for SpA patients treated in routine clinical practice.

Methods: The "EuroSpA" research network collaboration was established between registries collecting data on SpA patients. A survey was conducted via email and follow-up interviews April-December 2016 to assess patient numbers, data availability and completeness in participating registries. Our survey tool was based on key variables identified through literature review and expert interviews.

Results: 14 European rheumatology registries submitted information on their data covering approximately 63479 SpA patients, including patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) (Table).

Table 1. Approximate patient numbers in each SpA registry

Registry	Approximate patient numbers		
	PsA	AS	Nr-axSpA
ARC (Netherlands)		310	80
ARTIS (Sweden)	10000	10000	
ASRI (Ireland)		630	
ATTRA (Czech Republic)	800	2200	150
BIOBADASER (Spain)	500	500	20
Biorx.si (Slovenia)	350	600	
BSRBR-AS (Britain)		1500	650
DANBIO (Denmark)	7800	3900	3400
GISEA (Italy)	2400	1200	600
ICEBIO (Iceland)	376	343	
NOR-DMARD (Norway)	1600	1100	120
Reuma.pt (Portugal)	1600		2700
ROBFIN (Finland)	1900	1900	400
SCQM (Switzerland)	1900	1400	550
Total	29226	28283	5970

Data coverage was comprehensive for comorbidities, demographic and treatment variables, but limited for imaging and in PsA for skin and nail manifestations (figure).

Figure: Data items collected in 14 European rheumatology registries

Conclusions: A European research collaboration network of SpA registries, "EuroSpA", including ~ 63500 SpA patients enables the collection of key patient variables and strengthens research through increased patient numbers and cross-country comparative research. While core disease activity measures for SpA patients are widely collected, an enhanced standardized core dataset could strengthen future collaboration.

Acknowledgements: The authors acknowledge Craig Richardson from Novartis Pharma AG, Carol Lines and Seline Eisenring from Quintiles IMS for support in survey data collection and editorial assistance, and Novartis Pharma AG, Basel, Switzerland for financial support of the EuroSpA initiative.

Disclosure of Interest: M. L. Hetland Grant/research support from: AbbVie, BMS, MSD, Pfizer, Orion, Novartis, Biogen, Eli Lilly, M. Østergaard Grant/research support from: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, J. Asking: None declared, C. Gabay Grant/research support from: Roche, Pfizer, AB2 Bio, Consultant for: Sanofi, AB2 Bio, AbbVie, Pfizer, BMS, MSD, Roche, Novartis, D. Nordstrom: None declared, O. FitzGerald Grant/research support from: Pfizer, AbbVie, BMS, Novartis, UCB, Janssen, Celgene and Lilly, M. Hernández Miguel: None declared, M. Santos: None declared, Z. Rotar: None declared, H. Mann: None declared,

F. Iannone Consultant for: AbbVie, BMS, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, UCB, M. J. Nissen: None declared, E. Hauge: None declared, J. Gomez-Reino: None declared, F. Díaz-González: None declared, M. Tomsic: None declared, K. Pavelka: None declared, F. O'Shea: None declared, C. Sullivan: None declared, M. van de Sande: None declared, I. E. van der Horst-Bruinsma: None declared, G. J. Macfarlane Grant/research support from: Pfizer, AbbVie and UCB, G. T. Jones Grant/research support from: AbbVie, Pfizer, UCB, B. Gudbjörnsson: None declared, T. K. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB

DOI: 10.1136/annrheumdis-2017-eular.3659

FRI0451 SEX DIFFERENCES IN DISEASE ACTIVITY ACCORDING TO COMPOSITE INDICES IN SPONDYLOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Blasco-Blasco¹, I. Castrejón², V. Jovani³, E. Eliseo⁴, M. Ruiz-Cantero^{1,5}.

¹Public Health, University of Alicante, Alicante, Spain; ²Rheumatology, Rush University Medical Center, Chicago, United States; ³Rheumatology, Alicante University General Hospital; ⁴Rheumatology, Miguel Hernández University; ⁵Ciberesp, Alicante, Spain

Background: The Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), an index of only patient-self-report measures, and AS Disease Activity Score (ASDAS)¹, which adds patient global estimate and laboratory tests to BASDAI elements are widely used in Spondyloarthritis (SpA). Both indices are specifically designed to evaluate disease activity AS patients. Some studies have shown worse BASDAI in women, but sex-related differences by ASDAS remain unclear^{2,3}.

Objectives: To analyze reports of sex-stratified disease activity measures -BASDAI and ASDAS- in patients with SpA.

Methods: Data sources included PubMed (1950 to December 2016), Embase, Web Of Science, and manual searches of references lists. We included observational studies and randomized trials comparing disease activity scores, specifically BASDAI and ASDAS, between men and women with SpA. Studies quality was determined in line with the STROBE statement for observational studies and CONSORT statement for RCT, considering <50% positive items as low quality. Randomized effects were performed to report the mean difference (95% confidence interval) by gender, and heterogeneity was measured via I² statistic in order to check the results robustness.

Results: From 672 identified studies 18 cross-sectional studies, 3 cohort, 2 case-control studies, and 1 RTC reported sex-stratified BASDAI and ASDAS. ASDAS was evaluated in 3,758 patients (36.5% women) in 9 studies, and BASDAI included 12,329 patients (34.3% women) in 24 studies. In a metaanalysis of mean difference BASDAI including 19 studies the mean difference was 0.56 (95% CI: 0.47, 0.66) and I²=43%, indicating a significantly higher disease activity in women (Figure). In a metaanalysis of 7 studies ASDAS the mean difference was 0.06 (95% CI: -0.04, 0.16) and I²=41%, not showing statistically significant differences.

Figure. (A) Mean difference to BASDAI in men vs woman. (B) Mean difference to ASDAS in men vs woman

Conclusions: We identified relevant sex differences in disease activity according to BASDAI with higher disease activity in women, but not according to ASDAS. In SpA, women present more peripheral arthritis and higher pain, which may influence the BASDAI score, mainly based on patient-self-report measures. It is important to recognize these differences that may influence management decisions based on disease activity measures.

References:

- [1] van der Heijde D et al. Ann Rheum Dis 2009;68:1811–18.
- [2] van der Horst-Bruinsma IE et al. Ann Rheum Dis 2013;72:1221–1224.

[3] Arends S et al. *heumatology* 2015;54:1333–1335.
Acknowledgements: Faculty of Health Sciences and University Institute for Gender Studies of the University of Alicante supported M. Blasco-Blasco.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.4219

FRI0452 IMPACT OF A TRAINING PROGRAM AND EARLY REFERRAL ON DIAGNOSTIC DELAY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE SPANISH ATLAS

M. Garrido-Cumbrera¹, D. Galvez-Ruiz¹, V. Navarro-Compan², J. Gratacós-Masmitja³, C. Blanch Mur⁴, E. Collantes-Estevez⁵, P. Zarco-Montejo⁶, O. Braçe¹. ¹Universidad de Sevilla, Sevilla; ²H. la Paz, Madrid; ³H. Parc Tauli, Sabadell; ⁴Novartis, Barcelona; ⁵Universidad de Córdoba, Cordova; ⁶H. Fundación Alarcón, Madrid, Spain

Background: In patients with axial spondyloarthritis (axSpA), diagnosis delay (DD) postpones the initialisation of the most appropriate treatment with irreversible consequences on physical function, mobility and quality of life of patients. DD is also responsible for increased health costs resulting from incorrect referrals, visits to inappropriate health professionals and poorly planned diagnostic tests. Many initiatives have been undertaken in recent years in an attempt to reduce DD but their influence is still unknown.

Objectives: i) To determine diagnosis delay in patients with ax-SpA in Spain; ii) To assess the pre-diagnosis care process; iii) To analyse the possible beneficial effects on DD of a training programme for primary care physicians and early referral to rheumatology units.

Methods: A sample of 680 patients diagnosed with ax-SpA was interviewed during 2016 as part of the Atlas in Spain. This project aims to improve early diagnosis and to promote the use of effective treatments in ax-SpA patients. Collected data included: socio-demographics, medical visits prior to diagnosis, date for first symptoms and diagnosis and disease characteristics. This information was used to determine the DD and the possible beneficial effects on DD of a training programme for primary care physicians and early referral to rheumatology units. A descriptive analysis was performed, stratifying the results according to the start of the symptoms (before and after 2009). The ESPERANZA Program (a Spanish prospective multicentre national health programme aimed at facilitating early diagnosis of patients with ax-SpA) started in 2009.

Results: 53% of the patients included were females. Mean scores (standard deviation) were 45.7 (10.8) years for age and 12.4 (11.2) for disease duration. 77.1% were HLA-B27+. Visits to health professionals prior to diagnosis included: primary care physicians (88.5%), orthopaedic surgeons (71.7%), rheumatologists (70.4%), and physiotherapists (47.6%). The mean number of consultations prior to diagnosis was 2.6; 3.0; 2.0 and 3.4, respectively.

Patients stated the onset of the first ax-SpA symptoms was at mean 24.4 years of age, with diagnosis at mean 32.9 years of age, translating into a mean DD of 8.5 years. For 25% of patients DD was >12 years, whereas a DD of <2 years was found in only 25% of respondents. Mean DD for patients whose first symptoms appeared before 2009 was 9.5 years, whereas for patients whose first symptoms appeared after that date it was significantly reduced to 2.5 years.

Conclusions: The mean delay in diagnosis ax-SpA in Spain is above 8 years. Patients make a large number of visits to a variety of specialist physicians before they are diagnosed, which could point to proof of wrong referrals by primary care. However, DD has fallen drastically (to a mean 2.5 years) since the implementation of the ESPERANZA Program in 2009, suggesting that training primary care physicians have substantial beneficial effects on patients with ax-SpA and the care process.

Acknowledgements: This project has been supported by Novartis.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.6416

FRI0453 CLINICAL AND THERAPEUTIC CHARACTERIZATION OF A COLOMBIAN COHORT WITH SPONDYLOARTHRITIS

M.A. Alzate¹, F. Ramirez², F. Vargas², D. Hernandez-Parra¹, J.C. Salazar-Urbe³, P. Ortiz-Salazar¹, R. Pineda¹ on behalf of Artmedica IPS, Medellín, Colombia. ¹Clinical information group; ²Rheumatology division, Artmedica IPS; ³School of Statistics, Faculty of Sciences, National University of Colombia, Medellín, Colombia

Background: Spondyloarthropathies (SpAs) are a group of auto-inflammatory diseases, with overlapping symptoms, that include ankylosing spondylitis (AS), psoriatic arthritis (PsA), undifferentiated spondyloarthritis (Und SpA), enteropathic arthritis, and reactive arthritis (1).

Objectives: To characterize the disease in a large Colombian cohort with SpAs, assessing differences in its classification, clinical manifestations, laboratory results, radiographic changes, and treatment, according to the type of SpA.

Methods: A cross-sectional study was conducted in 621 patients with SpAs, in whom sociodemographic, clinical and therapeutic characteristics were analyzed based on the type of diagnosis. Statistical association was examined by means of Chi-square tests, Fisher's exact test, Mann-Whitney test, and logistic regression analyses. In all cases, a p value <0.05 was considered significant.

Results: Out of the 621 patients included, AS was observed in 54.7%, PsA in

35.7%, and Und SpA in 9.5%. AS was positively associated to male gender (OR 2.05 95%IC 1.5–2.8), younger age at onset, axial involvement (OR 23.2 95%IC 15.2–35.5), uveitis (OR 3.8 95%IC 2.25–6.57), radiographic sacroiliitis (OR 6.95 95%IC 3.02–16.02), and HLA-B27 positivity (OR 2.3 95%IC 1.5– 3.5). PsA was associated to female gender, older age at onset, arthritis, and peripheral involvement. According to the therapeutic approach, more use of conventional DMARD therapy was found in PsA and Und SpA, while more use of biology therapy in AS.

Table 1. General characteristics of patients with SpAs

	All N=621		AS N=340		PsA N=222		Und SpA N=59		p-value
	N	%	N	%	N	%	N	%	
Mean (SD)									
Age, year	49.3	(12.4)	45.2	(12.5)	56.7	(11.8)	45.9	(12.9)	<0.0001
Age at diagnostic, year	40.1	(12.9)	33.5	(12.6)	46.8	(13.5)	39.9	(12.5)	<0.0001
Male	328	52.8	208	61.1	96	43.2	24	40.6	<0.0001
Age at onset, <45 years	469	75.5	291	85.5	140	63.1	38	64.4	<0.0001
Low back pain	342	55.1	266	78.2	47	21.2	29	49.2	<0.0001
Arthritis	411	66.2	152	44.7	213	96	46	78	<0.0001
Enthesitis	217	34.9	136	40	37	16.7	44	74.6	0.38
Dactylitis	116	18.7	49	14.4	45	20.3	22	37.3	0.0002
Psoriasis	225	36.2	3	0.88	221	99.6	1	1.7	<0.0001
Uveitis	92	14.8	75	22.1	7	3.2	10	16.9	<0.0001
Family history	108	17.4	55	16.2	47	21.2	6	10.2	0.09
Sacroiliitis (Rx)	70/171	40.9	62/116	53.5	7/37	18.9	1/18	5.6	<0.0001
Sacroiliitis (MRI)	203/279	72.8	182/212	85.9	21/39	53.9	0/28	0.0	<0.0001
HLA-B27	284/438	64.8	229/321	71.3	17/61	27.9	38/56	67.9	<0.0001
Axial	397	63.9	328	96.5	37	16.8	32	54.2	<0.0001
Peripheral	488	78.6	213	62.6	218	98.2	57	96.6	<0.0001
Both	264	42.5	201	59.1	33	14.9	30	50.9	<0.0001

SD, standard deviation; Rx, radiography; MRI, Magnetic resonance.

Conclusions: To our knowledge, this is the larger existing cohort with SpAs in Colombia. Understanding the natural history of disease is important to do an early diagnosis and treatment that could prevent irreversible disability.

References:

[1] Ehrenfeld M. Spondyloarthropathies. *Best Pract Res Clin Rheumatol.* 2012;26(1):135–45.

Acknowledgements: None.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4906

FRI0454 M-SASSS AND CERVICAL SEGMENT C7-D1. SHOULD THE ORIGINAL SCORE BE MODIFIED?

M.J. Moreno-Martínez¹, M.J. Moreno-Ramos², L.F. Linares-Ferrando².
¹Rheumatology, H. Rafael Mendez; ²Rheumatology, H. U.Virgen de la Arrixaca, MURCIA, Spain

Background: Ankylosing Spondylitis is characterized by axial involvement. m-SASSS is the radiographic score that is used to evaluate the radiographic progression of the disease. It evaluates different lesions in the lumbar segment and in the cervical segment (from C2-C3 to C7-D1), both with a lateral x-ray. Theoretically, the C7-D1 intervertebral segment should not be evaluated through a simple lateral radiograph, but with x-rays in special positions.

Objectives: To evaluate the importance of the assessment of the C7-D1 intervertebral segment in patients with Ankylosing Spondylitis.

Methods: The patients come from a Spondyloarthritis Unit (Hospital Virgen of the Arrixaca, Murcia, Spain). All patients are diagnosed with Ankylosing Spondylitis (New York Modified Criteria)

The usual radiographic study was performed to calculate the m-SASSS (lateral cervical and lateral lumbar). We value the alterations found at level C7-D1 of patients and controls.

We compared the alterations found in patients with ankylosing spondylitis with control patients. These came from different rheumatology units, had no inflammatory pathology and had two lateral radiographs at different time periods. We collected demographic data (both from patients and from controls) and from clinical patients (analytical, activity and metrology).

Results: We included 47 patients (81% male and 19% female) with a mean age of 48 (± 8) years and a mean duration of symptoms of 18 (± 8.5) years. The mean time between the two radiographic studies was 3 (± 1.5) years. The control group was made up of 61 people (40, 7% men) with a mean age of 50 years (± 11).

The mean age of the control group was higher than patients (p=0.001). The C6-C7 intervertebral level could be assessed radiographically with the lateral cervical radiograph in 93.2% of the patients and in 85, 2% of controls, and the C7-D1 level was only assessed in 22, 7% of the patients and 50% of the controls. We analyzed whether the assessment of intervertebral level C7-D1 could be influenced by other variables such as sex, age or duration from the symptoms without finding a statistical result.

The 88, 5% of patients had a lower border of C7 normal or with squaring, erosion or sclerosis. Only 1 patient had syndesmophyte and 2 patients had a bridge between vertebrae. On the upper border of D1, 85, 5% of patients had normal or type-1 lesions (squarin, sclerosis or erosion), there wasn't syndesmophytes and 2 patients had a bridge (Table)